Redifferentiation therapy-induced radioiodine uptake in thyroid cancer

Journal of Nuclear Medicine

Volumn 39, Issue 11, 1998, Pages 1903-1906

  Grünwald, Frank ^a   Menzel, Christian ^a   Bender, Hans ^a   Palmedo, Holger ^a   Otte, Rolf ^a   Fimmers, Rolf ^a   Risse, Jörn ^a   Biersack, Hans J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Fluorodeoxyglucose PET; Radioiodine; Redifferentiation; Retinoic acid; Thyroglobulin; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE; ISOTRETINOIN; RADIOACTIVE IODINE; RETINOIC ACID; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; GLUCOSE METABOLISM; HORMONE SYNTHESIS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; THYROID CANCER; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, FOLLICULAR; AGED; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; ISOTRETINOIN; MALE; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031741959     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. DeGroot LJ, Kaplan EL, McCormick, M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
2. Schluniberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605.
3. Krishna L, Dadparvar S, Brady LW, et al. Paradoxic changes in iodine-131 scintigraphic findings in advanced follicular thyroid cancer. J Nucl Med 1993;34:1574-1576.
4. Vini L, Harmter C, McCready VR. Thyroid cancer: a review of treatment and follow-up. Ann Nucl Med 1996;10:1-7.
5. Biersack HJ, Helpap B, Koch U, Janson R, Baumgarten C, Winkler C. Should treatment of highly differentiated thyroid carcinoma be conservative? Nuklearmedizin 1983;22:20-23.
6. Oyen WJG, Mudde AH, van den Broek WJM, Corstens FHM. Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake. J Nucl Med 1995;36: 613-615.
7. Graf N, Riesinger P, Reinhard H. Retinoids in the treatment of acute promyelocytic leukemia. Review of the literature. Klin Padiatr 1995;207:43-47.
8. DeLaney TF, Afridi N, Taghian AG, et al. 13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res 1996;56:2277-2280.
9. Simon D, Koehrle J, Schmutzler C, Mainz K, Reiners C, Röher HD. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996;104(suppl 4):13-15.
10. Börner AR, Weckesser M, Langen KJ, Müller-Gärtner HW. First experiences with retinoic acid in metastatic differentiated thyroid cancer [Abstract]. Nuklearmedizin 1997;36:A67.
11. Spiessl B, Beahrs OH, Hermanek P, et al. 1993 TNM-Atlas. Illustrated guide for the TNM/pTNM-classification of malignant tumors/International Union Against Cancer/ Union Internationale Contre le Cancer (UICC). Berlin: Springer-Verlag, 1993.
12. Akslen LA, Prognostic importance of histological grading in papillary carcinoma. Cancer 1993;72:2680-2685.
13. Grünwald F, Ruhlmann J, Ammari B, Knopp R, Hotze A, Biersack HJ. Experience with a high-dose concept of differentiated metastatic thyroid cancer therapy. Nuklear-medizin 1988;27:266-271.
14. Biersack HJ, Hotze A. The clinician and the thyroid. Eur J Nucl Med 1991;18:761-778.
15. Wawschinek O, Eber O, Petek W, Wakonig P, Gürakar A. Estimation of urine iodine excretion using the modified ceric ion-arsenious acid reaction method. Ber ÖGKC 1985;8:13-15.
16. Hotze AL, Briele B, Grünwald F, et al. Determination of serum human thyroglobulin (hTg) with a new IRMA-system in patients with differentiated thyroid carcinoma. Radiol Diag 1991;32:383-386.
17. Schmutzler C, Brtko J, Bienert K, Köhrle J. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 199;104:16-19.
18. Van Herle AJ, Agatep M, Padua DN, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells in vitro. J Clin Endocrinol Metab 1990;71:755-763.
19. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-1472.
20. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
21. Sleeman MW, Zhou H, Rogers S, Ng KW, Best JD. Retinoic acid stimulates glucose transporter expression in L6 muscle cells. Mol Cell Endocrinol 1995;108:161-167.
22. Beierwaltes WH. Radioiodine therapy of thyroid disease. Nucl Med Biol 1987;14:177-181.
23. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-460.
24. Morris JC, Kim CK, Padilla ML, Mechanick JI. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. Thyroid 1997;7:63-66.